[Two drugs have been disqualified from being selected for national drug centralized procurement and related companies have been included in the list of violations] On October 27, the Joint Drug Procurement Office of the National Organization announced on October 26 that letrozole tablets produced by Eugia Pharma Specialities Limited and gadoterate dimeglumine injection produced by JSC Farmak will be disqualified from winning centralized procurement bids. The reason is that the applicants of the two aforementioned companies have recently stated that they are unable to continue to supply products, and after interviews and supervision, they are still unable to meet the needs of medical institutions. Currently, Eugia Pharma Specialities Limited and its reporting companies Hangzhou Ketu Supply Chain Co., Ltd., JSC Farmak and Shanghai Liyi Pharmaceutical Technology Co., Ltd. have all been included in the violation list and have been disqualified from participating in the national drug centralized procurement within 4 years and 2 years. (Interface News)